Research
P21 — living evidence map
The Atlas page holds the claims; this is how its evidence evolved.
Summary
P021 is a small neurotrophic and neurogenic peptide mimetic compound, developed to avoid the blood-brain barrier impermeability, short half-life and side effects that halted trials of whole neurotrophic factor proteins in Alzheimer's disease. · pmid:36291618
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Proportion of the 1 claim about P21 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for P21 yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
- Approved-label dose · a resolved regulatory document names a labelled dose
nothing resolved on this rung
- Studied human doses · resolved human studies at the established tier
nothing resolved on this rung
- Observational evidence · resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
- Community-reported protocols · protocol propositions from distinct members, counted once per human
nothing resolved on this rung
- Preclinical evidence · resolved animal, cell or mechanistic work
- Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound. · pmid 36291618 · 2022
1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.